The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

The FGFR TKI erdafitinib continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations.

Momelotinib provided a statistically significant benefit in terms of splenic symptoms, anemia, and splenic size in patients with myelofibrosis.

Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.

Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.

Naval Daver, MD, discusses the latest developments in acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and follicular lymphoma.

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

Ravin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.

James P. Allison, PhD, permanently etched his legacy into immuno-oncology with the development of ipilimumab, work that helped him win a Giants of Cancer Care® award for Scientific Advances in 2014.

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.

Naval Daver, MD, discusses he encouraging early data that has been reported with KO-539 and other menin inhibitors in acute myeloid leukemia, data presented with novel KO-539 combinations in this disease, and next steps for research.

Despite their rarity, the management of desmoid tumors has been an area of significant clinical change as the field has shifted away from aggressive surgical interventions to active surveillance and systemic therapies that are less morbid for patients.

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Elise Nassif, MD, discusses the evolving standard of care for patients with soft tissue sarcoma and the benefits of early phase inclusion, as well as histotype testing for this population.

Preclinical evidence suggests that pairing KO-539 with targeted agents directed against BCL-2, BET, and CDK6 could result in superior efficacy against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

Alexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.

The novel non-covalent BTK inhibitor pirtobrutinib showed promising preclinical efficacy in overcoming ibrutinib and venetoclax resistance, and in limiting cell growth and inducing apoptosis in mantle cell lymphoma.